Skip to main content
ARS Home » Southeast Area » Athens, Georgia » U.S. National Poultry Research Center » Endemic Poultry Viral Diseases Research » Research » Publications at this Location » Publication #321085
Title: Multiple efficacy studies of an adenovirus-vectored foot-and-mouth disease virus serotype A24 subunit vaccine in cattle using direct homologous challenge

Author
item SCHUTTA, CHRISTOPHER - Us Deparment Of Homeland Security
item BARRERA, JOSE - Us Deparment Of Homeland Security
item PISANO, MELIA - Us Deparment Of Homeland Security
item Zsak, Laszlo
item GRUBMAN, MARVIN - Retired ARS Employee
item MAYR, GREGORY - Animal And Plant Health Inspection Service (APHIS)
item MORAES, MAURO - Ceva Animal Health
item KAMICKER, BARBARA - Us Deparment Of Homeland Security
item BRAKE, DAVID - Us Deparment Of Homeland Security
item ETTYREDDY, DAMODAR - Genvec, Inc
item BROUGH, DOUGLAS - Genvec, Inc
item BUTMAN, BRYAN - Genvec, Inc
item NEILAN, JOHN - Us Deparment Of Homeland Security

Submitted to: Vaccine
Publication Type: Peer Reviewed Journal
Publication Acceptance Date: 12/8/2015
Publication Date: 6/8/2016
Citation: Schutta, C., Barrera, J., Pisano, M., Zsak, L., Grubman, M.J., Mayr, G.A., Moraes, M.P., Kamicker, B.J., Brake, D.A., Ettyreddy, D., Brough, D.E., Butman, B.T., Neilan, J.J. 2016. Multiple efficacy studies of an adenovirus-vectored foot-and-mouth disease virus serotype A24 subunit vaccine in cattle using direct homologous challenge. Vaccine. 34(27):3214-3220. doi: 10.1016/j.vaccine.2015.12.018.

Interpretive Summary: A human adenovirus-vectored foot-and-mouth disease virus (FMDV) vaccine was shown to be safe and protected against virulent homologous FMDV challenge. No detectable local or systemic reactions were observed after vaccination and no clinical disease was observed following virulent virus challenge of vaccinated cattle. The vectored vaccine enabled differentiation of infected from vaccinated cattle prior to challenge.

Technical Abstract: The safety and efficacy of an experimental, replication-deficient, human adenovirus-vectored foot-and-mouth disease virus (FMDV) serotype A24 Cruzeiro capsid-based subunit vaccine (AdtA24) was examined in eight independent cattle studies. AdtA24 non-adjuvanted vaccine was administered intramuscularly to a total of 150 steers in doses ranging from approximately 1.0 × 108to 2.1 × 1011particle units per animal. No detectable local or systemic reactions were observed after vaccination. At 7 days post-vaccination (dpv), vaccinated and control animals were challenged with FMDV serotype A24 Cruzeiro via the intra-dermal lingual route. Vaccine efficacy was measured by FMDV A24 serum neutralizing titers and by protection from clinical disease and viremia after challenge. The results of eight studies demonstrated a strong correlation between AdtA24 vaccine dose and protection from clinical disease (R2= 0.97) and viremia (R2= 0.98). There was also a strong correlation between FMDV A24 neutralization titers on day of challenge and protection from clinical disease (R2= 0.99). Vaccination with AdtA24 enabled differentiation of infected from vaccinated animals (DIVA) as demonstrated by the absence of antibodies to the FMDV nonstructural proteins in vaccinates prior to challenge. Lack of AdtA24 vaccine shedding after vaccination was indicated by the absence of neutralizing antibody titers to both the adenovector and FMDV A24 Cruzeiro in control animals after co-mingling with vaccinated cattle for three to four weeks. In summary, a non-adjuvanted AdtA24 experimental vaccine was shown to be safe, immunogenic, consistently protected cattle at 7 dpv against direct, homologous FMDV challenge, and enabled differentiation of infected from vaccinated cattle prior to challenge.